Work

Outcomes of patients with stage I–II Hodgkin lymphoma who had uniform pre-treatment staging with PET/CT and treatment with limited field radiation therapy after chemotherapy

Year: 2022

Type: article

Abstract: Combined modality therapy (CMT) consisting of chemotherapy followed by radiation therapy (RT) is an accepted standard of care for stage I-II Hodgkin lymphoma (HL). The German Hodgkin Study Group trials HD7-HD11 [ 1 ] helped to establish the parameters for CMT, ultimately leading to HD10 and HD11 and adoption of 20 Gy and 30 Gy, using involved field RT (IFRT), as the standard dose of RT following ABVD for favorable and unfavorable HL, respectively. Relapse has not to be eliminated, however. For example, the HD10 trial reported a 10 year progression-free survival rate of 87% [ 1 ].

Source: Blood Cancer Journal

DOI: 10.1038/s41408-022-00711-8